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1ABSTRACT 
Background: Serous cystic neoplasms of the pancreas are regarded as a benign entity 
with rare malignant potential.  Surgical resection is generally considered curative.  
Objective: To perform the largest single institution review of patients who underwent 
surgical resection for serous cystic neoplasms of the pancreas in the hopes of guiding 
future management. 
Methods: Between June 1988 and January 2005, 158 patients with serous cystic 
neoplasms of the pancreas underwent surgical resection.  A retrospective analysis was 
performed.  Univariate and multivariate models were used to determine factors 
influencing perioperative morbidity and mortality.  Major complications were defined as 
pancreatic fistula or anastomotic leak, postoperative bleed, retained operative material, or 
death.  Minor complications were defined as wound infection, postoperative 
obstruction/ileus requiring TPN, delayed gastric emptying, arrhythmia, or other infection. 
Results: The mean age of the patients was 62.1 years, with 75% being female.  The 
majority of patients were symptomatic at presentation (63%), with abdominal pain as the 
most common symptom.  Of the 158 patients, 75 underwent distal pancreatectomy, 65 
underwent pancreaticoduodenectomy, 9 underwent central pancreatectomy, 5 underwent 
local resection or enucleation, and 4 underwent total pancreatectomy.  Mean tumor 
diameter was 5.1 cm.  Mean operative time was 277.5 minutes.  Mean postoperative 
length of hospital stay was 11 days.  One patient was diagnosed at presentation with 
serous cystadenocarcinoma.  The remaining 157 patients were initially diagnosed with 
benign serous cystadenoma.  One of three patients with locally aggressive benign disease  
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later presented with metastatic disease.  Resection margins for all 158 patients were 
negative for tumor, and only 1 (0.6%) showed lymph node involvement.  There was one 
intraoperative death.  The incidence of major perioperative complications was 18%, 
while the incidence of minor complications was 33%.  Men were significantly more 
likely to experience minor perioperative complications (OR = 3.74, P = .008), while 
patients greater than 65 years showed a trend toward fewer major complications (OR = 
0.36, P = .09). 
Conclusions: Serous cystic neoplasms of the pancreas which are surgically resected are 
typically seen in asymptomatic women, as 5 cm neoplasms which are predominantly 
benign.  Most are resected via either a left or right sided pancreatectomy with low 
mortality risk, but with notable major or minor morbidity.  Cystadenocarcinoma is a rare 
finding on initial resection of serous cystic neoplasms.  However, initial pathology 
specimens exhibiting benign but locally aggressive neoplasia may indicate an increased 
likelihood of recurrence or metachronous metastasis.   
 
3. 
 
INTRODUCTION 
 
Serous cystic neoplasms (SCNs) of the pancreas are almost always benign.  They 
are one of the most common primary pancreatic cystic neoplasms, and are distinguished 
from mucinous cystic neoplasms (MCNs) and intraductal papillary mucinous neoplasms 
(IPMNs) (1).   SCNs constitute 10-15% of all cystic masses of the pancreas and 1-2% of 
all pancreatic neoplasms (2,3).  However, SCNs are being increasingly diagnosed with 
more widespread use and improving technology of imaging techniques (4,5).  These 
neoplasms show a predilection for middle-aged and older women and are often 
discovered incidentally (6).  Symptoms are frequently non-specific, with abdominal pain 
being the most common, occurring in 50-60% of all cases (7).  Computed tomography is 
thought to be the diagnostic test of choice to properly identify this tumor type (8).  SCNs 
are typically unifocal and present as large, well-demarcated, often honeycombed cystic 
masses which can grow as large as 25 cm.  Diffuse or multifocal disease is uncommon.  
The cysts are loculated, consist of mucin-free serous fluid, and are surrounded by 
cuboidal or flattened epithelium. (9)     
Unlike MCNs and IPMNs, SCNs are generally regarded as almost always benign, 
though their potential for malignant conversion remains a topic of debate (10).  Due in 
large part to the uncertainty over malignant potential and the natural history of the 
disease, currently there is no accepted standard of treatment or follow-up for SCNs.  For 
many, observation and routine surveillance are preferred (11).  Some investigators 
recommend complete resection of all SCNs because of the perceived malignant potential 
of the disease, the relative frequency of symptoms and complications, and the challenge  
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of an accurate preoperative diagnosis (2,12,13).  Those that utilize a selective approach 
advocate for resection in the setting of tumors that are symptomatic, poorly defined, and 
larger sized (7,14).  Indeed, symptomatology appears to be the predominant and only 
universally accepted indication for operative intervention.  In all cases, resection is 
considered curative, with no postoperative surveillance recommended. 
The goals of our large (158 patients) single institution review were to evaluate 
clinical parameters, pathologic features, and overall patient outcome following resection 
of SCNs of the pancreas, in the hopes of guiding future management.   
5. 
METHODS 
Between June 1988 and January 2005, 158 patients with serous cystic neoplasms 
of the pancreas underwent surgical resection.  A retrospective analysis of a database was 
performed.  The study was approved by the Institutional Review Board for Human 
Research and complied with Health Insurance Portability and Accountability Act 
(HIPAA) regulations.   
Major complications were defined as pancreatic fistula or anastomotic leak, 
postoperative bleed, retained operative material, or death.  Minor complications were 
defined as wound infection, postoperative obstruction/ileus requiring TPN, bowel 
obstruction responsive to conservative non-operative treatment, delayed gastric emptying, 
arrhythmia, or other infection.  Follow-up data were collected from postoperative 
admissions and/or clinic visits.  Univariate and multivariate models were used to 
determine factors influencing perioperative morbidity and mortality.  The chi square test 
was used for comparison between categorical outcome variables versus categorical 
independent variables, while t test was used to compare between continuous outcome 
variables versus categorical independent variables.  Multiple logistic regression was used 
in final analysis.  Statistical significance was defined as p<0.05.  Statistical analysis was 
performed using Stata 9.  Data are given as mean +/- standard deviation, where 
appropriate. 
 
6. 
RESULTS 
 
Demographics  
 Table 1 outlines the patient population in our series. The mean age of patients 
was 62.1. + 13.3 years with most patients being non-Hispanic whites (81%).  The 
majority of patients (75%) were female.  There was no significant difference in age of 
presentation between males and females.   
Presentation 
Most patients presented with symptoms (64%).  The most common symptoms 
were abdominal pain (74%), weight loss (22%), nausea/vomiting (10%), jaundice (6%), 
and GI bleed (3%).  Men tended to be symptomatic more than women (45% of men 
versus 34% of women, not significant).  Symptoms did not correlate with location or size 
of tumor.  Of 158 patients, 66 (42%) underwent a computed tomography (CT) scan at our 
institution while the remaining were referred and treated with outside studies.  Figure 1 
shows two representative CT scans of patients with SCNs.    
Operative and Postoperative Course 
 All patients in this series were treated operatively.  Of the 158 patients, 75 (47%) 
underwent distal pancreatectomy for neoplasm of the body or tail of the pancreas, 65 
(41%) underwent pancreaticoduodenectomy for right-sided tumors, 9 (6%) underwent 
central pancreatectomy for neoplasms of the neck or proximal body, 5 (3%) underwent 
local resection or enucleation, and 4 (3%) underwent total pancreatectomy for neoplasms 
extensively involving the gland.  The average operative time was 277.5 minutes.  The 
average transfusion requirement was 0.8 + 3.9 units of packed red blood cells.  There was  
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one operative death due to intraoperative hemorrhage from visceral vessels.  Overall, the 
incidence of major complications was 18% while the incidence of minor complications 
was 33%.  The most common major complication was pancreatic leak or fistula with an 
incidence of 13%.   Men were significantly more likely to have minor complications than 
women (OR = 3.75, p = .008).  Patients >65 years of age also showed a trend toward 
fewer major complications (OR = 0.36, p = .088).  Table 2 and Table 3 describe 
complications by age and gender respectively.  Mean postoperative length of hospital 
stay was 11.3 (SD = 8.9 days).   
Pathology 
 For 158 resected tumors, the mean tumor size was 5.1 cm + 3.7 cm.  Tumors were 
located in the head (42%), body or tail (48%), proximal neck or body (7%), and with 
diffuse involvement of the entire gland (3%).  Tumor size did not significantly vary by 
tumor location.  Of all 158 patients, one patient at primary resection was noted to have 
biopsy proven serous cystic neoplasm of the liver and was therefore diagnosed with 
serous cystadenocarcinoma.  The remaining 157 patients were diagnosed at primary 
resection with serous cystadenoma of the pancreas.  Of these 157 patients, 3 were noted 
in final pathology report to have “locally aggressive disease” on histologic examination.  
One of these 3 patients recurred 13 years later with disease in the liver and retroperitoneal 
tissue and was therefore diagnosed with serous cystadenocarcinoma. 
 
8. 
DISCUSSION 
Classified as a benign neoplasm, serous cystic neoplasm (SCN) of the pancreas is 
the most common primary cystic neoplasm of the pancreas and accounts for 1-2% of all 
primary pancreatic neoplasms (1).   SCNs had long been classified with mucinous cystic 
neoplasms, until Compagno and Oertel as well as Hodgkinson and others defined and 
separated serous from mucinous cystic neoplasms (15, 16).  They recognized that the 
mucinous variants such as mucinous cystic neoplasms (MCNs) and intraductal papillary 
mucinous neoplasms (IPMNs) have a significantly greater malignant potential than 
SCNs.   
George et al. first introduced a malignant variant known as serous 
cystadenocarcinoma (10).  There have since been multiple case reports of malignant SCN 
histologically indistinguishable from benign SCN of the pancreas but marked by 
malignant behavior, most commonly invasive or metastatic disease (12,17-23).  One 
study suggested that up to 3% of reported SCNs were in fact malignant or had malignant 
potential (8).  This malignant variant is defined by the presence of metastases to 
extrapancreatic organs or tissues (24).  Vascular and perineural invasion, and local 
invasion into the duodenum or stomach, are not criteria for the diagnosis of malignancy.  
There currently exists no consensus for management of SCNs.  Many advocate 
simple surveillance given the almost universally benign nature of the disease and the 
relative morbidity and mortality associated with resection (11).  However, a schedule of 
surveillance which adequately defines when expectant management should yield to  
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intervention has yet to be agreed upon.  Furthermore, because other cystic neoplasms of 
the pancreas have significant malignant potential, it is imperative that the diagnosis of 
SCN be certain before committing to expectant management and surveillance.  Others 
support a selective approach to resection based on symptoms, tumor size, or 
indeterminate preoperative diagnosis, among other factors (13,14).  There continue to be 
those who support resection of all SCNs.  They cite the real, albeit rare, malignant 
potential, the risk of an incorrect preoperative diagnosis, and the potential for symptoms 
and complications.  Resection is generally considered curative and no postoperative 
monitoring is advocated. 
Here we report the largest single institution experience with SCNs to date.  The 
mean age of the 158 patients was 62.1 years with 75% being female (Table 1).  This is 
consistent with previous studies which have also shown a predilection for the disease in 
middle aged to elderly females.  Most patients were symptomatic at presentation (64%).  
Among symptomatic patients, the most common symptoms were abdominal pain (74%), 
weight loss (22%), nausea/vomiting (10%), jaundice (6%), and GI bleed (3%).  The 
proportion of symptomatic patients is similar to or higher than that found in most other 
reviews.  (8,14,15)  The higher rate of symptomatic patients may partly be explained by 
the extensive referral nature of the practice at Johns Hopkins.  In our series, 41% of the 
SCNs arose in the head of the pancreas, 48% in the body or tail, 6% in the neck or 
proximal body, and only 3% of lesions exhibited diffuse involvement of the entire gland.  
Mean tumor diameter was 5.1 cm, similar to the size found in Tseng et al.’s  
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contemporary series (14).  All resection margins were negative, with only one SCN 
exhibiting lymph node involvement.  There was one intraoperative death, due to 
excessive hemorrhage.  In our experience, surgery for these lesions carried minimum 
mortality risk (0.6%) but notable major (18%) and minor (33%) morbidity risk.  This risk 
of complications approximates the risk of pancreatic surgery for other conditions (such as 
adenocarcinoma of the pancreas) but the mortality rate for resection of SCN is less (25).  
It is worth noting that males had a significantly greater risk of experiencing minor 
complications than women.  The reasons for this difference are not immediately apparent 
and warrant further investigation.  No patient died of his or her disease. This fact, in 
conjunction with the aforementioned risks of surgery, would support a cautious approach 
to the resection of these neoplasms.  
In our series, only 0.6% (1/158) of the patients with an SCN presented with 
metastatic disease.  This patient presented initially with multifocal disease in the pancreas 
and liver, and was therefore diagnosed with a serous cystadenocarcinoma.  Indeed, after 
resection of her pancreatic tumor, she returned to clinic one year later with extensive 
growth of a biopsy proven SCN in the liver which was nonoperable.  Remarkably, both 
her primary and the liver metastases had a histologically bland appearance, lacking both 
architectural and cytologic atypia.  An additional 3 patients in this study were noted to 
have “locally aggressive” neoplasms at the time of initial resection.  These neoplasms 
were histologically identical to the more benign behaving tumors, but showed locally 
aggressive behavior by growing into neighboring structures (Figure 2).  Margins were 
negative for these tumors.  One of these patients returned in follow-up 13 years after  
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resection with biopsy proven recurrence in the liver and retroperitoneal soft tissue.  
Again, both the primary and the liver metastases had a histologically bland appearance, 
lacking both architectural and cytologic atypia.  As this represented an extrapancreatic 
recurrence, the diagnosis for this patient was adjusted to reflect a serous 
cystadenocarcinoma.  Thus, a total of two of the 158 patients (1.3%) in this series either 
presented with or ultimately developed metastatic disease. 
Currently, resection for SCN is considered curative with no follow-up beyond 
postoperative care recommended.  Here we report one case of recurrence following 
resection of the primary tumor.  This tumor exhibited locally aggressive behavior at time 
of initial resection.  Only two of the remaining 157 resected specimens exhibited a 
similar pattern.  Locally aggressive growth therefore may offer an important clue as to 
which neoplasms have the potential to recur as cystadenocarcinoma.  It will be interesting 
to follow the 2 additional patients whose tumors exhibited locally aggressive growth.  
Their lack of metastatic disease or recurrence may be explained by the fact that their 
primary resections were relatively recent (1999 and 2000) as compared to the primary 
resection for the patient whose disease later recurred (1992).  Further follow-up of this 
tumor characteristic is warranted, and may offer a tool in determining a subpopulation of 
patients who do not have metastases at presentation, but for whom additional follow-up 
surveillance is warranted. 
The proper management of patients with a SCN remains elusive.  The first step is 
to distinguish this lesion from the more aggressive and premalignant lesions: IPMNs and 
MCNs.  Beyond that, there are divergent paths.  Based on our findings, we propose the  
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following algorithm (Figure 3).  If SCN cannot confidently be distinguished from MCN 
or IPMN, the patient should undergo resection.  When the diagnosis of SCN is 
confidently determined based on clinical and radiographic evidence, perhaps only 
symptomatic tumors should be resected.  If the decision is made to avoid resection 
initially, we do recommend serial imaging at a 6 to 12 months interval, with resection for 
growth (more than 1 cm change in diameter) or the development of symptoms.  Post 
resection, gross and microscopic review of the neoplasm should document not only the 
presence or absence of metastases, but also any locally aggressive growth.  For 
neoplasms exhibiting this rare characteristic, patients should be counseled that although 
in most cases SCNs are cured with primary resection, a small sub-population of cases 
may recur, and may require additional imaging follow-up and treatment, as indicated.       
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n (%)   Mean + SD 
Total patients                                                         158 
Sex 
 Male     70 (25) 
 Female     118 (75) 
Age (years)        62.1 + 13.2 
Symptomatic     101 (64) 
 Abdominal pain    75 (47) 
 Weight loss    22 (14) 
 Nausea/vomiting    10 (6) 
 Jaundice     6 (4) 
 Gastrointestinal bleed   3 (2) 
Operation 
 Distal pancreatectomy, splenectomy 75 (47) 
 Whipple     65 (41) 
 Central pancreatectomy   9 (6) 
 Local resection or enucleation  5 (3) 
 Total pancreatectomy   4 (3) 
Tumor size (cm)        5.1 + 3.7 
Operative time (minutes)       277.5 + 117.4 
Hospital stay (days)       11.3 + 8.9  
Death      1 (0.6)  
Major complication    29 (18)† 
 Hemorrhage    2 (1.2) 
 Pancreatic leak    21 (13) 
 Bile leak    5 (3) 
 Retained operative material  1 (0.6) 
Minor complication    52 (33)* 
 Wound infection    8 (5) 
 Delayed gastric emptying   5 (3) 
 Postoperative ileus   4 (2) 
 Arrhythmia     8 (5) 
 Other infection    21 (12) 
Final pathologic diagnosis 
 Serous cystadenoma   156 (98) 
 Serous cystadenocarcinoma  2 (2)** 
TABLE 1: Patient characteristics.  †Patients greater than 65 years showed a 
trend toward fewer major complications (OR = 0.36, P = .09).  *Men had 
significantly more minor complications than women (OR = 3.74, p = .008).  
** One patient who was diagnosed with serous cystadenoma on initial 
resection later recurred and was therefore re-diagnosed with 
cystadenocarcinoma. 
3 65 years > 65 years p value 
Number of patients           89   69  
 
Major Complications (total)           19    9  .088 
 Hemorrhage           1    1 
 Pancreatic leak                14                     7 
 Bile leak               3    2 
 Retained operative material         1    0 
 
Minor Complications (total)          31   19   N.S. 
 Wound infection                  4                  4 
 Delayed gastric emptying                3    2 
 Postoperative ileus           3     1 
 Small bowel obstruction*                 3                 0 
 Arrhythmia            5    3 
 Deep Vein Thrombosis                 1                  0 
 Other infection                 12    9 
 
TABLE 2: Complications compared with age of patients.  Note that patients greater than 
65 years showed a trend toward fewer major complications (OR = 0.36, P = .09).   
 
Male Female p value 
 
Number of patients           40        118 
 
Major Complications (total)           6         23    N.S. 
 Hemorrhage           0          2 
 Pancreatic leak               6         15 
 Bile leak                0          5 
 Retained operative material         0                      1 
 
Minor Complications (total)          17         33   .008 
 Wound infection                 3          5 
 Delayed gastric emptying                 1          4 
 Postoperative ileus          1          3 
 Small bowel obstruction*                 1          2 
 Arrhythmia           3          5 
 Deep Vein Thrombosis                       1          0 
 Other infection                        7         14 
 
TABLE 3: Complications compared with patient gender.  Note that males had 
significantly more minor complications than women (OR = 3.74, p = .008).
FIGURE LEGENDS 
 
FIGURE 1: Computed tomography (CT) scans of two patients, each with serous 
cystadenoma of the pancreas.  The image on the right is from a 64 year old female who 
presented with abdominal pain.  Her 10 cm neoplasm in the head of the pancreas was 
resected with a Whipple procedure without complication.  The image on the left is from a 
59 yo female who presented with pain and “fullness.”   Her 27 cm mass originating from 
the tail of the pancreas was resected with a distal pancreatectomy and splenectomy 
without complication.  
FIGURE 2: Locally aggressive SCN.  Although classically benign, SCNs may rarely 
exhibit locally aggressive behavior.  In one patient, tumor compresses the pancreatic duct 
(a).  On microscopic examination, this neoplasm exhibits bland histological appearance, 
lacking both architectural and cytologic atypia (b).  However, this SCN shows 
uncommon locally aggressive behavior by growing up against and into a neighboring 
lymph node (arrows).  
FIGURE 3: Proposed approach to the patient with a cystic neoplasm of the pancreas. 
b
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